The PwC Pharma and Life Sciences experts are pleased to present you with the fifth issue of our Asia-Pacific pharmaceutical industry newsletter
In this issue, we have two special reports for you. This first is on Saratoga, PwC’s human capital measurement and benchmarking arm which recently set up an Asia-Pac dedicated centre in Singapore. This initiative has stated to benchmark Asia-Pac companies and build the database to complement the existing extensive database available from US and EU based companies. The second report is to inform you on the 2011 Indian Budget for the Pharma sector.
Taiwan and China signed a new drug development pact and agreed on mutual recognition based on compliance with international guidelines. You can read more details on this in the compliance section.
Good news if you want to register your products in Taiwan and the products are already on the US and EU markets, as the review period will be cut in half. Read about it in the regulatory section.
Recently the Indian government has proposed new measures to improve clinical trials, more stringent penalties to offenders who trade in spurious drugs and mandatory bar-codes on products for export starting 1 July 2011. More details on these three key developments in India in the regulatory section.
In Australia, the National Health Administration Bill has now become law with some minor changes. Follow up on this topic from our last newsletter in the pricing and reimbursement section. In the same section you can read how the Chinese government is progressing with price cuts of drugs and taking away the premium pricing that some of the originator drugs were enjoying.
Catch up on the latest tax news from multiple territories: Indonesia, Japan, Korea, Malaysia, New Zealand, Singapore and Taiwan in the tax section.
We trust that the information is of use to you and your organisation. If you would like to discuss any topic in more detail, feel free to reach out to your PwC territory contact or the experts mentioned in the article.